《NDT,3月20日,Recommendations for the prevention, mitigation and containment of the emerging SARS-CoV-2 (COVID-19) pandemic in haemodialysis centres》

  • 来源专题:COVID-19科研动态监测
  • 编译者: zhangmin
  • 发布时间:2020-03-23
  • Recommendations for the prevention, mitigation and containment of the emerging SARS-CoV-2 (COVID-19) pandemic in haemodialysis centres

    Carlo Basile, Christian Combe, Francesco Pizzarelli, Adrian Covic, Andrew Davenport, Mehmet Kanbay, Dimitrios Kirmizis, Daniel Schneditz, Frank van der Sande, Sandip Mitra on behalf of the EUDIAL Working Group of ERA-EDTA

    Nephrology Dialysis Transplantation, gfaa069, https://doi.org/10.1093/ndt/gfaa069

    Published: 20 March 2020

    Abstract

    COVID-19, a disease caused by a novel coronavirus, is a major global human threat that has turned into a pandemic. This novel coronavirus has specifically high morbidity in the elderly and in comorbid populations. Uraemic patients on dialysis combine an intrinsic fragility and a very frequent burden of comorbidities with a specific setting in which many patients are repeatedly treated in the same area (haemodialysis centres). Moreover, if infected, the intensity of dialysis requiring specialized resources and staff is further complicated by requirements for isolation, control and prevention, putting healthcare systems under exceptional additional strain. Therefore, all measures to slow if not to eradicate the pandemic and to control unmanageably high incidence rates must be taken very seriously.

  • 原文来源:https://academic.oup.com/ndt/advance-article/doi/10.1093/ndt/gfaa069/5810637?searchresult=1
相关报告
  • 《MedRxiv,3月20日,SARS-CoV-2 specific antibody responses in COVID-19 patients》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-03-22
    • SARS-CoV-2 specific antibody responses in COVID-19 patients NISREEN M.A. OKBA, Marcel A Muller, Wentao Li, Chunyan Wang, Corine H. GeurtsvanKessel, Victor M. Corman, Mart M. Lamers, Reina S. Sikkema, Erwin de Bruin, Felicity D. Chandler, Yazdan Yazdanpanah, Quentin Le Hingrat, Diane Descamps, Nadhira Houhou-Fidouh, Chantal B. E. M. Reusken, Berend-Jan Bosch, Christian Drosten, Marion P.G. Koopmans, Bart L. Haagmans doi: https://doi.org/10.1101/2020.03.18.20038059 Abstract A new coronavirus, SARS-CoV-2, has recently emerged to cause a human pandemic. Whereas molecular diagnostic tests were rapidly developed, serologic assays are still lacking, yet urgently needed. Validated serologic assays are important for contact tracing, identifying the viral reservoir and epidemiological studies. Here, we developed serological assays for the detection of SARS-CoV-2 neutralizing, spike- and nucleocapsid-specific antibodies. Using serum samples from patients with PCR-confirmed infections of SARS-CoV-2, other coronaviruses, or other respiratory pathogenic infections, we validated and tested various antigens in different in-house and commercial ELISAs. *注,本文为预印本论文手稿,是未经同行评审的初步报告,其观点仅供科研同行交流,并不是结论性内容,请使用者谨慎使用.
  • 《LANCET,3月17日,Prevention of SARS-CoV-2 infection in patients with decompensated cirrhosis》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-03-18
    • Prevention of SARS-CoV-2 infection in patients with decompensated cirrhosis Yong Xiao Hong Pan Qian She Fen Wang Mingkai Chen Published:March 17, 2020DOI:https://doi.org/10.1016/S2468-1253(20)30080-7 We read the Comment by Chao Zhang and colleagues1 in The Lancet Gastroenterology & Hepatology on liver injury in coronavirus disease 2019 (COVID-19) with great interest. Given that patients with decompensated cirrhosis have a higher risk of, and mortality from, infection, preventing infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in this patient population is a challenging task.2 We provide our experience of COVID-19 prevention in patients with decompensated cirrhosis in Wuhan, China.